Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 47.79 Million EUR | 33.53% |
| 2022 | 34.43 Million EUR | 28.52% |
| 2021 | 26.79 Million EUR | 137.87% |
| 2020 | 11.26 Million EUR | 72.85% |
| 2019 | 6.51 Million EUR | -22.89% |
| 2018 | 8.45 Million EUR | -16.69% |
| 2017 | 10.14 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 12.56 Million EUR | 9.34% |
| 2024 Q2 | 13.19 Million EUR | 9.82% |
| 2023 Q1 | 11.66 Million EUR | 17.89% |
| 2023 Q3 | 11.62 Million EUR | -7.52% |
| 2023 Q2 | 12.57 Million EUR | 7.79% |
| 2023 FY | 45.97 Million EUR | 33.53% |
| 2023 Q4 | 11.49 Million EUR | -1.17% |
| 2022 Q2 | 7.99 Million EUR | 4.44% |
| 2022 Q1 | 7.65 Million EUR | 13.65% |
| 2022 FY | 34.43 Million EUR | 28.52% |
| 2022 Q3 | 8.89 Million EUR | 11.32% |
| 2022 Q4 | 9.89 Million EUR | 11.18% |
| 2021 Q2 | 6.41 Million EUR | 17.52% |
| 2021 Q3 | 8.19 Million EUR | 27.74% |
| 2021 FY | 26.79 Million EUR | 137.87% |
| 2021 Q4 | 6.73 Million EUR | -17.8% |
| 2021 Q1 | 5.45 Million EUR | 21.91% |
| 2020 Q3 | 3.89 Million EUR | 150.32% |
| 2020 Q1 | 2.05 Million EUR | -13.92% |
| 2020 FY | 11.26 Million EUR | 72.85% |
| 2020 Q4 | 4.47 Million EUR | 14.98% |
| 2020 Q2 | 1.55 Million EUR | -24.15% |
| 2019 Q3 | 2.38 Million EUR | 68.72% |
| 2019 Q4 | 2.38 Million EUR | 0.0% |
| 2019 Q2 | 1.41 Million EUR | 0.0% |
| 2019 FY | 6.51 Million EUR | -22.89% |
| 2019 Q1 | 1.41 Million EUR | 0.0% |
| 2018 FY | 8.45 Million EUR | -16.69% |
| 2017 FY | 10.14 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | 54.163% |
| AngioDynamics, Inc. | 252.41 Million USD | 81.065% |
| AtriCure, Inc. | 327.05 Million USD | 85.386% |
| Avinger, Inc. | 18.63 Million USD | -156.433% |
| Azenta, Inc. | 336.26 Million USD | 85.787% |
| BioLife Solutions, Inc. | 117.57 Million USD | 59.351% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 97.381% |
| Daxor Corporation | 1.28 Million USD | -3632.405% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -97.569% |
| Femasys Inc. | 15.2 Million USD | -214.428% |
| GlucoTrack, Inc. | 7.1 Million USD | -572.776% |
| Harvard Bioscience, Inc. | 58.58 Million USD | 18.414% |
| Hologic, Inc. | 1.34 Billion USD | 96.447% |
| ICU Medical, Inc. | 717.04 Million USD | 93.335% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 98.387% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -83.064% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | 47.094% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 40152.292% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 40152.292% |
| Masimo Corporation | 867 Million USD | 94.487% |
| Microbot Medical Inc. | 9.85 Million USD | -384.972% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -159.467% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 89.608% |
| Nephros, Inc. | 9.78 Million USD | -388.491% |
| NovoCure Limited | 613.92 Million USD | 92.215% |
| NEXGEL, Inc. | 4.09 Million USD | -1066.846% |
| NEXGEL, Inc. | 4.09 Million USD | -1066.846% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | 53.255% |
| OraSure Technologies, Inc. | 125.34 Million USD | 61.869% |
| Pro-Dex, Inc. | 7.37 Million USD | -547.791% |
| Pulse Biosciences, Inc. | 43.57 Million USD | -9.685% |
| Predictive Oncology Inc. | 15.22 Million USD | -213.825% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -460.824% |
| QuidelOrtho Corporation | 1.35 Billion USD | 96.474% |
| Repligen Corporation | 261.12 Million USD | 81.697% |
| Sanara MedTech Inc. | 61.12 Million USD | 21.812% |
| STAAR Surgical Company | 224.55 Million USD | 78.716% |
| Sharps Technology, Inc. | 10.12 Million USD | -371.963% |
| Utah Medical Products, Inc. | 13.26 Million USD | -260.41% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 97.336% |
| Jin Medical International Ltd. | 3.91 Million USD | -1119.99% |